Fixed-dose combination
Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate is a fixed-dose combination of an osmotic laxative, a calculi dissolution agent and a potassium salt. MedsAcross supplies Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is indicated for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older. Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adult and pediatric patients 12 years of age and older.
Source: US FDA prescribing information
Sulfate salts provide sulfate anions, which are poorly absorbed. The osmotic effect of unabsorbed sulfate anions and the associated cations causes water to be retained within the gastrointestinal tract.
Source: US FDA prescribing information
Preparation and Administration. Must dilute in water prior to ingestion. Administration of two bottles of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is required for a complete preparation for colonoscopy. One bottle is equivalent to one dose. Must consume additional water after each dose. Stop consumption of all fluids at least 2 hours before the colonoscopy. Recommended Dosage and Administration Split-Dose (two-day) regimen consists of two doses of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution: first dose during the evening prior to colonoscopy and second dose the next day, during the morning of colonoscopy. Recommended Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution dosage is: º Adults: Two 6-ounce doses. º Pediatric Patients 12 Years of Age and Older: Two 4.5-ounce doses.
Source: US FDA prescribing information
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is contraindicated in the following conditions: Gastrointestinal obstruction or ileus Bowel perforation Toxic colitis or toxic megacolon Gastric retention Hypersensitivity to any of the ingredients in Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution Gastrointestinal obstruction or ileus. Bowel perforation. Toxic colitis or toxic megacolon. Gastric retention. Hypersensitivity to any ingredient
Source: US FDA prescribing information
Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after each use. Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold. Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing. Suspected GI obstruction or perforation: Rule out the diagnosis before administration. Patients at risk for aspiration: Observe during administration.
Source: US FDA prescribing information
Most common adverse reactions are: Adults (>2%): overall discomfort, abdominal distention, abdominal pain, nausea, and vomiting. Pediatric Patients (>10%): nausea, abdominal pain, abdominal bloating and vomiting. The following important adverse reactions for bowel preparations are described elsewhere in the labeling: Serious Fluid and Serum Chemistry Abnormalities Cardiac Arrhythmias Seizures Use in Patients with Risk of Renal Injury Colonic Mucosal Ulceration and Ischemic Colitis Patients with Significant Gastrointestinal Disease Aspiration
Source: US FDA prescribing information
Drugs that increase risk of fluid and electrolyte imbalance. Drugs That May Increase Risks of Fluid and Electrolyte Abnormalities Use caution when prescribing Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution to patients taking medications that increase the risk of fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F). Excursions permitted between 15° to 30°C (59° to 86°F). See USP controlled room temperature.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate 1.2 g/2.35 g/13.13 g per 133.1 mL oral concentrateOralGeneric name | Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate | — | US FDA | Available on request |
| Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate 1.6 g/3.13 g/17.5 g per 177 mL oral solutionOralGeneric name | Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate | — | US FDA | Available on request |
| Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate 1.6 g/3.13 g/17.5 g per mL oral concentrateOralGeneric name | Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate | — | US FDA | Available on request |
| SUPREP Bowel Prep 1.2 g/2.35 g/13.13 g per 133.1 mL oral concentrateOral | Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate | Azurity Pharmaceuticals | US FDA | Available on request |
| SUPREP Bowel Prep 1.6 g/3.13 g/17.5 g per mL oral concentrateOral | Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate | Azurity Pharmaceuticals | US FDA | Available on request |
| Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Bowel Prep kit 1.6 g/3.13 g/17.5 g per 177 mL oral solutionOral | Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
2 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 2 brand names for Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate, including Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Bowel Prep kit, SUPREP Bowel Prep.
No listed presentation of Magnesium sulfate, unspecified form, Potassium sulfate and Sodium sulfate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.